Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07417618 · ClinicalTrials.gov registry record
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
A clinical trial of Type 2 Diabetes and Overweight, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 60,000
- Enrollment target
- 1
- Study location
NCT07417618: Active study of Type 2 Diabetes and Overweight, sponsored by Brigham and Women's Hospital.
NCT07417618 is a study of Type 2 Diabetes and Overweight that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 60,000 participants, above the 3,740-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (1504% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07417618, a study of Type 2 Diabetes and Overweight, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 60,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Hazard ratio of the composite of myocardial infarction, stroke, or all-cause mortality in individuals with T2DM and overweight with ASCVD, comparing dulaglutide, semaglutide, and tirzepatide vs sitagliptin.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Sitagliptin
- DRUG Semaglutide
- DRUG Dulaglutide
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60,000 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2026-03 |
What the registry record for NCT07417618 still lists
NCT07417618 is an observational study that tracks outcomes without assigning an intervention. Its 60,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,740-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (1504% higher).
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 4 interventions - of which Tirzepatide is the first listed.
NCT07417618 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07417618 about?
NCT07417618 is a clinical study titled "INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07417618?
This trial is currently active not recruiting. The enrollment target is 60,000 participants. The study started on 2026-01-27. Estimated completion is 2026-03.
What conditions does trial NCT07417618 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Overweight, ASCVD.
What interventions are being tested in trial NCT07417618?
The interventions under investigation include: Tirzepatide (DRUG), Sitagliptin (DRUG), Semaglutide (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT07417618?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07417618 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07417618's enrollment target sits among peer trials
60,000 4th of 327 higher than 324 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00785525 · 60,000 participants · Phase 3
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
- NCT01825499 · 60,000 participants
Vermont Oxford Network Very Low Birth Weight Database
- NCT02850588 · 60,000 participants
SVS VQI TransCarotid Revascularization Surveillance Project
- NCT03752840 · 60,200 participants · NA
Village-Integrated Eye Worker Trial II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI